Navigation Links
Nutraceutical Reports Q3 Results
Date:7/31/2008

PARK CITY, Utah, July 31 /PRNewswire-FirstCall/ -- Nutraceutical International Corporation (Nasdaq: NUTR) today reported results for the fiscal 2008 third quarter ended June 30, 2008. Net sales for the fiscal 2008 third quarter were $40.5 million compared to $38.7 million for the same quarter of fiscal 2007. For the third quarter of fiscal 2008, net income was $2.9 million, or $0.26 diluted earnings per share, compared to net income of $2.9 million, or $0.25 diluted earnings per share, for the same quarter of fiscal 2007.

Net sales for the nine months ended June 30, 2008 were $126.0 million compared to $116.6 million for the same period in fiscal 2007. For the nine months ended June 30, 2008, net income was $10.4 million, or $0.93 diluted earnings per share, compared to net income of $10.4 million, or $0.92 diluted earnings per share, for the same period of fiscal 2007.

Operating cash flow for the nine months ended June 30, 2008 was $14.4 million compared to $15.6 million for the same period of fiscal 2007. This operating cash flow, combined with net borrowings of $10.0 million, was used to invest $14.1 million in property and equipment, $5.9 million in acquisitions of branded natural product businesses and $4.2 million in repurchases of common stock.

Bill Gay, chairman and chief executive officer, commented, "The growth in net sales for our fiscal 2008 third quarter came from the integration of our fiscal 2007 and 2008 acquisitions into our brands. Operational synergies from manufacturing have enabled us to increase gross profit margins and provide continued strong operating cash flows. Raw material costs have increased but our focus on sourcing has allowed us to mitigate the impact to date. We continue to invest in marketing and sales in an effort to improve our competitive position while consolidating these acquisitions into the company. It is important for us to remain promotionally competitive with the health food stores we serve during this economically challenging period. We intend to continue to focus on addressing labor and other cost pressures.

We also continue to explore potentially non-dilutive and affordable acquisitions that will help us achieve our long-term growth objectives for sales and profitability. Our business model and the industry we serve demonstrates how a long-term, value driven company like ours is able to produce solid results during times when consumers seem to be watching their pocket books. We appreciate and thank everyone that supports us in our efforts to improve our business."

ABOUT NUTRACEUTICAL

We are an integrated manufacturer, marketer, distributor and retailer of branded nutritional supplements and other natural products sold primarily to and through domestic health and natural food stores. Internationally, we market and distribute branded nutritional supplements and other natural products to and through health and natural product distributors and retailers. Our core business strategy is to acquire, integrate and operate, from beginning to end, the manufacturing, marketing and distribution of branded nutritional supplement businesses in the natural products industry. We believe that the consolidation and integration of these acquired businesses provides ongoing financial synergies through increased scale and market penetration, as well as strengthened customer relationships.

We sell branded nutritional supplements and other natural products under the trademarks Solaray(R), VegLife(R), KAL(R), Nature's Life(R), Sunny Green(R), Action Labs(R), Natural Balance(R), NaturalMax(R), bioAllers(R), Herbs for Kids(TM), Natra-Bio(R), NaturalCare(R), Zand(R), Health from the Sun(R), Life-flo(R), Larenim(R), Living Flower Essences(R), Pioneer(R), Thompson(R), Natural Sport(R), Supplement Training Systems(R), Premier One(R), Montana Big Sky(TM), ActiPet(R), FunFresh Foods(TM), Dowd & Rogers(TM), CompliMed(R), AllVia(TM), Oakmont Labs(R), Healthway(R), Body Gold(R), Sayge BioSciences(TM), Monarch Nutritional Laboratories(TM) and Great Basin Botanicals(TM). Under the name Woodland Publishing(TM), we publish, print and market a line of books and booklets to, among others, book distributors, national retail bookstores and health and natural food stores. We also distribute branded products of certain third parties.

We own neighborhood natural food markets, which operate under the trade names The Real Food Company (TM), Thom's Natural Foods(TM) and Cornucopia Community Market(TM). We also own health food stores, which operate under the trade names Fresh Vitamins(TM), Granola's(TM) and Pilgrim's Natureway(TM).

We manufacture and/or distribute one of the broadest branded product lines in the industry with over 3,900 SKUs, including over 700 SKUs sold internationally. We believe that as a result of our emphasis on innovation, quality, loyalty, education and customer service, our brands are widely recognized in health and natural food stores and among their customers.

This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements relate to our future plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these statements. We undertake no obligation to update forward- looking statements to reflect events or circumstances occurring after the date of this Press Release. Important factors that may cause our results to differ from these forward-looking statements include, but are not limited to, government regulations, product liability claims and litigation, insurance coverage issues, a decrease in or slowing of the growth rate of the vitamin, mineral and supplement market, the success of the healthy foods channel, consumer perception of safety and quality of our products and similar products, competition, intellectual property rights of other parties, the loss of key personnel, disruptions from acquisitions, issues with obtaining raw materials of adequate quality or quantity, problems with information management systems, manufacturing efficiencies and operations, litigation generally, the volatility of the stock market generally and of our stock specifically, a general lack of adequate industry analyst coverage, and other factors indicated from time to time in our SEC reports, copies of which are available upon request from our investor relations group or which may be obtained at the SEC's website (http://www.sec.gov).

(C) 2008 Nutraceutical Corporation. All rights reserved.

NUTRACEUTICAL INTERNATIONAL CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited; dollars in thousands)

June 30, September 30,

2008 2007

Assets

Current assets, net $54,887 $51,534

Property, plant and equipment, net 49,975 39,506

Goodwill 40,980 38,978

Other non-current assets, net 16,081 16,384

$161,923 $146,402

Liabilities and Stockholders' Equity

Current liabilities $18,123 $20,275

Long-term liabilities 30,923 20,208

Stockholders' equity 112,877 105,919

$161,923 $146,402

NUTRACEUTICAL INTERNATIONAL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited; dollars in thousands, except per share data)

Three months Nine months

ended June 30, ended June 30,

2008 2007 2008 2007

Net sales $40,454 $38,694 $125,986 $116,646

Cost of sales 18,489 17,889 57,192 53,193

Gross profit 21,965 20,805 68,794 63,453

Operating expenses

Selling, general and

administrative 16,933 15,730 50,539 45,688

Amortization of

intangible assets 185 121 522 230

Income from operations 4,847 4,954 17,733 17,535

Interest and other

(income)/expense, net 223 352 1,008 814

Income before provision

for income taxes 4,624 4,602 16,725 16,721

Provision for income taxes 1,771 1,749 6,309 6,354

Net income $2,853 $2,853 $10,416 $10,367

Net income per common share

Basic $0.26 $0.26 $0.94 $0.94

Diluted 0.26 0.25 0.93 0.92

Weighted average common

shares outstanding

Basic 10,964,696 11,047,027 11,043,026 11,027,237

Diluted 11,097,500 11,251,405 11,181,609 11,234,775

NUTRACEUTICAL INTERNATIONAL CORPORATION

EBITDA SCHEDULE

(unaudited; dollars in thousands)

Three months Nine months

ended June 30, ended June 30,

2008 2007 2008 2007

Net income $2,853 $2,853 $10,416 $10,367

Provision for income taxes 1,771 1,749 6,309 6,354

Interest and other (income)/expense,

net (1) 223 352 1,008 814

Depreciation and amortization 1,514 1,236 4,256 3,501

EBITDA $6,361 $6,190 $21,989 $21,036

(1) Includes amortization of deferred financing fees.


'/>"/>
SOURCE Nutraceutical International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Dermatologists In Denial: Controversial New Chocolate Nutraceutical Claims to be Good for Your Skin
2. Photos: For the First Time Researchers Show Reversal of an Aging Marker in the Human Retina Correlated with Visual Improvement Using a Nutraceutical Matrix (Longevinex(R))
3. Berkeley Premium Nutraceuticals Pushes Forward
4. Direct Response TV Course on Nutraceutical/Cosmeceutical Products to Premiere in New York City
5. Nellson Nutraceutical Names New Directors and Interim Chief Executive Officer
6. Nutraceutical Reports Fiscal 2008 Q1 Results
7. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
8. NutraCea Forms Joint Ventures With HerbalScience to Develop Nutraceutical Extracts and Pharmaceutical Chemistries From Stabilized Rice Bran
9. Nutraceutical Reports 2007 Fiscal Year End Results
10. New Nutraceutical Supplement Provides Simplified Approach to Diabetes Management Programs
11. New Nutraceutical That Stabilizes Blood Sugar Naturally is Introduced
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... MA (PRWEB) , ... December 08, 2016 , ... ... Workers Compensation Research Institute (WCRI) officially opened registration today for its 33rd ... Hotel in Boston, MA . , The theme of the conference is “Persistent ...
(Date:12/8/2016)... PLAINS, N.Y., and JENNERSVILLE, Pa. (PRWEB) , ... ... ... to announce that Penn Medicine Southern Chester County, a Property owned by an ... The $23 million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care ...
(Date:12/8/2016)... , ... December 08, 2016 , ... With the increasing ... the “What’s In Your Mouth?” (WIYM) campaign to inform dentists and patients about the ... the dental implant and prosthetic market in the U.S. is projected to reach $6.4 ...
(Date:12/8/2016)... ... 08, 2016 , ... SunView Software aims to redefine IT ... both engaging and easy to use. Coming off the heels of a successful ... its plans to roll out new AI-powered self-service enhancements to help organizations implement ...
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ... been recognized for adherence to the highest standards of trauma, maternity, cancer and ... the center's president and CEO, Dr. Daniel Messina. , Among the recognitions, the ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)...  A Mederi Therapeutics Inc . anunciou aprovação regulatória, pela CFDA, e ... doença do refluxo gastroesofágico (DRGE). Foto -  http://photos.prnewswire.com/prnh/20161207/446903 ... ... Live Stretta procedure performed and broadcast during the Chinese Congress of Digestive Endoscopy, ... , , ...
(Date:12/8/2016)... CITY , Dec. 8, 2016 ... US patents for improving the accuracy, reproducibility and ... images in long and small bone orthopaedic applications. ... approach to creating personalized orthopaedic restorations based on ... personalized orthopaedic restorations, the company harnesses the world,s ...
(Date:12/8/2016)... 2016  Valeant Pharmaceuticals International, Inc. (NYSE: ... announced positive results from a Phase 3, multicenter ... safety and efficacy of IDP-118 (halobetasol propionate and ... Within the Phase 3 study ... psoriasis, IDP-118 showed statistical significance to vehicle with ...
Breaking Medicine Technology: